Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review
Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders and NMDA hypofunction. The company through its subsidiaries operates in the US, Bermuda, Germany, Switzerland, England and Wales. Sage is headquartered in Cambridge, Massachusetts, the US.
Sage Therapeutics Inc Key Recent Developments
Sep 21,2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer
Aug 03,2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 20,2021: Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
May 04,2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Apr 20,2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders and NMDA hypofunction. The company through its subsidiaries operates in the US, Bermuda, Germany, Switzerland, England and Wales. Sage is headquartered in Cambridge, Massachusetts, the US.
Sage Therapeutics Inc Key Recent Developments
Sep 21,2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer
Aug 03,2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 20,2021: Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
May 04,2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Apr 20,2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Sage Therapeutics Inc - Key Facts
Sage Therapeutics Inc - Key Employees
Sage Therapeutics Inc - Key Employee Biographies
Sage Therapeutics Inc - Major Products and Services
Sage Therapeutics Inc - History
Sage Therapeutics Inc - Company Statement
Sage Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sage Therapeutics Inc - Business Description
R&D Overview
Sage Therapeutics Inc - Corporate Strategy
Sage Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sage Therapeutics Inc - Strengths
Sage Therapeutics Inc - Weaknesses
Sage Therapeutics Inc - Opportunities
Sage Therapeutics Inc - Threats
Sage Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sage Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 21, 2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer
Aug 03, 2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 20, 2021: Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
May 04, 2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Apr 20, 2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Mar 16, 2021: Sage Therapeutics Announces Departure of Chief Operating Officer
Feb 24, 2021: Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
Feb 11, 2021: Sage Therapeutics to Present at Upcoming Investor Conferences
Feb 10, 2021: Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
Jan 07, 2021: Sage Therapeutics provides 2021 corporate strategy update at J.P. Morgan Healthcare Conference
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Sage Therapeutics Inc - Key Facts
Sage Therapeutics Inc - Key Employees
Sage Therapeutics Inc - Key Employee Biographies
Sage Therapeutics Inc - Major Products and Services
Sage Therapeutics Inc - History
Sage Therapeutics Inc - Company Statement
Sage Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Sage Therapeutics Inc - Business Description
R&D Overview
Sage Therapeutics Inc - Corporate Strategy
Sage Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sage Therapeutics Inc - Strengths
Sage Therapeutics Inc - Weaknesses
Sage Therapeutics Inc - Opportunities
Sage Therapeutics Inc - Threats
Sage Therapeutics Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sage Therapeutics Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 21, 2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer
Aug 03, 2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 20, 2021: Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
May 04, 2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Apr 20, 2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Mar 16, 2021: Sage Therapeutics Announces Departure of Chief Operating Officer
Feb 24, 2021: Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
Feb 11, 2021: Sage Therapeutics to Present at Upcoming Investor Conferences
Feb 10, 2021: Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
Jan 07, 2021: Sage Therapeutics provides 2021 corporate strategy update at J.P. Morgan Healthcare Conference
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Sage Therapeutics Inc, Key Facts
Sage Therapeutics Inc, Key Employees
Sage Therapeutics Inc, Key Employee Biographies
Sage Therapeutics Inc, Major Products and Services
Sage Therapeutics Inc, History
Sage Therapeutics Inc, Subsidiaries
Sage Therapeutics Inc, Key Competitors
Sage Therapeutics Inc, Ratios based on current share price
Sage Therapeutics Inc, Annual Ratios
Sage Therapeutics Inc, Annual Ratios (Cont...1)
Sage Therapeutics Inc, Interim Ratios
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sage Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Sage Therapeutics Inc, Key Facts
Sage Therapeutics Inc, Key Employees
Sage Therapeutics Inc, Key Employee Biographies
Sage Therapeutics Inc, Major Products and Services
Sage Therapeutics Inc, History
Sage Therapeutics Inc, Subsidiaries
Sage Therapeutics Inc, Key Competitors
Sage Therapeutics Inc, Ratios based on current share price
Sage Therapeutics Inc, Annual Ratios
Sage Therapeutics Inc, Annual Ratios (Cont...1)
Sage Therapeutics Inc, Interim Ratios
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sage Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Sage Therapeutics Inc, Performance Chart (2016 - 2020)
Sage Therapeutics Inc, Ratio Charts
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Sage Therapeutics Inc, Performance Chart (2016 - 2020)
Sage Therapeutics Inc, Ratio Charts
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021